Global Pipeline Our R&D portfolio currently consists of: - New Chemical Entities in various fields, such as neurology and analgesia. - New Advanced Therapies for inherited metabolic disorders. Our portfolio and continued commitment to R&D, together with our manufacturing capacity, have allowed us to receive an "Excellent" rating in Group A of the Spain's Profarma Plan (Plan to Promote Scientific Research, Technological Development and Innovation in the Pharmaceutical Industry) continuously since 1986. ESTEVE is implementing various programs that are currently in diverse stages of research and development. SMALL MOLECULE GENE THERAPY Therapeutic areas Description Moderate-to-Severe Acute Pain E-58425: a novel, first-in-class co-crystal of Celecoxib and Tramadol Neuropathic Pain E-52862: a novel, first-in-class NCE selective Sigma-1 antagonist Mucopolysaccharidosis Type IIIA EGT-101: a potential first-in-class AAV-9 gene therapy administered via a one-time intracerebroventricular injection into the cerebrospinal fluid Pain-Related Disorders (Undisclosed) MUMO-1: a novel, first-in-class NCE with a multi-modal mechanism of action that includes Sigma-1 antagonism Mucopolysaccharidosis Type IIIB EGT-201: a potential first-in-class AAV-9 gene therapy Mucopolysaccharidosis Type II EGT-301: a potential first-in-class AAV-9 gene therapy Undisclosed MUMO-5: a novel, first-in-class NCE with multimodal mechanisms of action Lysosomal Storage Disorder (Undisclosed) A potential first-in-class gene therapy Neurodegenerative Disorders (Undisclosed) Unique Sigma-1 Platform of agonists and antagonists Internal projects with public financing The internal projects developed in collaboration with multiple centres were financed mainly with Esteve's own resources, to which some competitive public grants has been added. Esteve has neither requested nor has it ever received funding from patients' associations or private individuals. E-52862 has received grants from the Spains's Ministry of Economy and Competitiveness, via the Centre for Industrial Technological Development (CDTI) for clinical validation in neuropathic pain, as well as the projects Multimodal-1, Multimodal-2, Multimodal-3, Multimodal-5 and Sigma-1 new indications, that have also been partially co-financed by the European Union via the European Regional Development Fund (ERDF). Project E-58425 has received a grant by the Catalonia Trade & Investment Agency (ACC1Ó) of the Generalitat de Catalunya as part of the line of loans for industrial innovation and experimental development projects via the Catalan Institute of Finance (ICF). The Sanfilippo project has received grants from the Spain's Ministry of Economy and Competitiveness and the Ministry of Health, Social Policy and Equality, in competitive calls for research projects, in which the project was recognized for its scientific excellence. Get to know our scientific publications Read more About us Who we are Corporate governance Our global presence Our commitment Therapeutic areas Contract Manufacturing R&D Research Areas Pipeline Scientific publications Patients B2B Partnering Media Corporate resources Contact Adverse reactions Work with us Privacy Legal notice Cookies policy Last update 11/11/2021 | © 1996-2021 ESTEVE Use of cookies We use our own and third-party cookies for analytic, technical and profiling purposes; we process data that is needed to create profiles based on your browsing habits. Press the "ACCEPT COOKIES" button to confirm their use. You can change the configuration of your cookies by pressing "MORE INFORMATION AND CONFIGURATION". ACCEPT COOKIES MORE INFORMATION AND CONFIGURATION * *This option allows you to reject the cookies.